Lifeboat Foundation

Nanotechnology offers specific benefits that will enable the future of cancer care. Find out here what these are.

A gene editing tool using a system known as CRISPR-Cas9 has recently been approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease. The drug is known as Casgevy and the media has hailed this treatment as a ‘cure’ for sickle cell anemia patients. While it is still unclear if the drug completely cures these patients, clinical trials show exciting efficacy.

Sickle cell disease is a genetic blood disorder affecting thousands of US citizens. Many of these patients are African American and Hispanic. In sickle cell disease, hemoglobin, a protein in red blood cells that helps carry oxygen throughout the body, is mutated. As a result, blood cells change shape in the form of a sickle, giving the disease its name. Unfortunately, the mutated cells cause disruption of blood flow and prevent other blood cells from delivering oxygen to the body. This disease is extremely rare and can lower the quality of life in patients. Previously, there were limited treatments options including transfusions and medications for pain management. However, Casgevy provides a new option to help treat the patient and relieve pain for over a year after a single treatment.

One-time treatment using Casgevy improved life quality for sickle cell patients. A single-arm trial was conducted at multiple health centers in adults and adolescents. These patients were screened for two vaso-occlusive crises (VOCs) which are described as severely painful events due to a lack of oxygen delivery from sickle cell blood cells blocking blood flow. The primary measure of success in the trial was the number of VOCs after treatment. In total, 44 patients received Casgevy and 33 were able to follow up and be evaluated. Of the 33 patients that made it through the trial, 29 of them did not experience any VOCs for 12 months. This is a 93.5% success rate based on the number of patients that were analyzed. All 44 patients were able to successfully undergo treatment without any graft rejection. In addition, researchers concluded that this treatment was not only effective, but safe with few side effects.

When imaginations are unconstrained, you end up with electric vehicles like the Hummer EV SUV.

Join the discussion on this paper page.

We’re on a journey to advance and democratize artificial intelligence through open source and open science.

Join the discussion on this paper page.

After unearthing its fossils in 2017, researchers now reveal a new species of penguin called Kumimanu fordycei that weighed over 340 pounds.

Researchers mapped over 10,000 mouse hippocampal #neurons, creating the world’s most comprehensive database of single-neuron #connectivity #patterns.

Summary: Researchers unveiled the most extensive single-neuron projectome database to date, featuring over 10,000 mouse hippocampal neurons.

The study provides an unprecedented view of the spatial connectivity patterns at the mesoscopic level, crucial for understanding learning, memory, and emotional processing in the hippocampus. By employing machine learning algorithms for categorizing axonal trajectories and integrating spatial transcriptome data, researchers identified 43 distinct projectome cell types, revealing intricate projection patterns and soma locations’ correspondence to projection targets.

Continue reading “Mapping the Brain: The Largest Neuron Projectome Unveiled” »

The first reviews for Vision Pro are live, highlighting a ton of great, good and not-so-great things about Apple’s first mixed reality headset.

The $3,500 Vision Pro is set to launch on February 2nd, but it seems the first reviews are already out from a select number of outlets, including CNET, The Verge, The Wall Street Journal, and CNBC.

Continue reading “The First Apple Vision Pro Reviews Are Here” »